Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignancy in patients with sickle cell disease.

William H Schultz1, Russell E Ware

  • 1Duke University Medical Center, Durham, North Carolina 27710, USA.

American Journal of Hematology
|November 25, 2003
PubMed
Summary

Cancer risk in sickle cell disease (SCD) is being studied. This review identified 52 malignancy cases in SCD patients, providing baseline data for future research, especially concerning hydroxyurea therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Seroprotection after Measles Vaccination in Children with Sickle Cell Anemia Receiving Hydroxyurea.

Blood advances·2026
Same author

Hydroxyurea interferes with point-of-care creatinine testing in children with sickle cell anemia.

BMC research notes·2026
Same author

Ten Years of Hydroxyurea for Ugandan Children with Sickle Cell Anemia.

The New England journal of medicine·2026
Same author

Persistent Splenomegaly Is Associated with Morbidity in Tanzanian Children with Sickle Cell Anemia: Secondary Analysis of the SPHERE Trial.

Acta haematologica·2026
Same author

Growth and puberty in African children with sickle cell anemia treated with hydroxyurea.

Blood advances·2026
Same author

Sickle Cell Disease in Sub-Saharan Africa: Progress and Potential.

American journal of hematology·2026

Area of Science:

  • Hematology
  • Oncology
  • Pediatrics

Background:

  • Malignancy incidence and types in sickle cell disease (SCD) are not well-defined.
  • Concerns exist regarding hydroxyurea therapy potentially increasing cancer risk in SCD patients.

Purpose of the Study:

  • To establish baseline data on cancer incidence and types in patients with SCD.
  • To assess the relationship between malignancy and hydroxyurea use in SCD.

Main Methods:

  • A retrospective review of 52 cancer cases (49 patients) in individuals with SCD.
  • Data collected from 52 institutions through the International Association of Sickle Cell Nurses and Physician Assistants.

Main Results:

  • The median age at diagnosis was 34 years; 40% of cases were in pediatric patients (leukemia, Wilms' tumor).
  • Adults predominantly developed solid tumors (carcinomas); survival rates were lower in adults compared to children.
  • Three patients had received hydroxyurea prior to malignancy diagnosis.

Conclusions:

  • This study provides crucial baseline data for understanding cancer in SCD patients.
  • Further research is needed to clarify cancer risks, particularly in those undergoing hydroxyurea therapy.

Related Experiment Videos